TP53 and neoplasm: These findings suggest that OBP-702-mediated p53 activation in p53-intact tumor cells is a promising approach for enhancing the antitumor efficacy of Ad-p53 DC vaccine therapy by sensitizing tumor cells to p53-targeting CTLs.